Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Jun;7(6):569–574. doi: 10.1111/j.1365-2125.1979.tb04644.x

Pharmacokinetics, pharmacology of atenolol and effect of renal disease.

S H Wan, R T Koda, R F Maronde
PMCID: PMC1429677  PMID: 465278

Abstract

1. The pharmacokinetics of intravenous and oral atenolol (50 mg) in six healthy volunteers was studied. Plasma, saliva and urine were collected up to 24 h after each dose. 2. There was no significant difference in atenolol half-life when administered by the two routes. Bioavailability of the orally administered atenolol was 50%. 3. Atenolol levels in saliva required about 2 h to reach equilibrium with plasma drug levels. 4. A comparison between the pharmacokinetics and pharmacology of atenolol was made in twelve healthy subjects. 5. Dose-independent pharmacokinetics were observed. Reductions in resting heart rate and arterial blood pressure were proportional to either the logarithm of dose or area under the plasma concentration time curve or cumulative urinary atenolol excretion. 6. Plasma elimination half-life in five subjects with renal failure was prolonged.

Full text

PDF
569

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amery A., Billiet L., Joossens J. V., Meekers J., Reybrouck T., Van Mieghem W. Preliminary report on the haemodynamic response of hypertensive patients treated with a beta blocker (ICI 66082). Acta Clin Belg. 1973;28(5):358–363. doi: 10.1080/17843286.1973.11716888. [DOI] [PubMed] [Google Scholar]
  2. Amery A., De Plaen J. F., Lijnen P., McAinsh J., Reybrouck T. Relationship between blood level of atenolol and pharmacologic effect. Clin Pharmacol Ther. 1977 Jun;21(6):691–699. doi: 10.1002/cpt1977216691. [DOI] [PubMed] [Google Scholar]
  3. Barrett A. M., Carter J., Fitzgerald J. D., Hull R., Le Count D. A new type of cardioselective adrenoceptive blocking drug. Br J Pharmacol. 1973 Jun;48(2):340P–340P. [PMC free article] [PubMed] [Google Scholar]
  4. Brown H. C., Carruthers S. G., Johnston G. D., Kelly J. G., McAinsh J., McDevitt D. G., Shanks R. G. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther. 1976 Nov;20(5):524–534. doi: 10.1002/cpt1976205524. [DOI] [PubMed] [Google Scholar]
  5. Conway F. J., Fitzgerald J. D., McAinsh J., Rowlands D. J., Simpson W. T. Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol. 1976 Apr;3(2):267–272. doi: 10.1111/j.1365-2125.1976.tb00602.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hainsworth R., Karim F., Stoker J. B. Blockade of peripheral vascular responses to isoprenaline by three beta-adrenoceptor antagonists in the anaesthetized dog. Br J Pharmacol. 1974 Jun;51(2):161–168. doi: 10.1111/j.1476-5381.1974.tb09643.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hansson L., Aberg H., Jameson S., Karlberg B., Malmcrona R. Initial clinical experience with I.C.I. 66.082, a new beta-adrenergic blocking agent, in hypertension. Acta Med Scand. 1973 Dec;194(6):549–550. doi: 10.1111/j.0954-6820.1973.tb19489.x. [DOI] [PubMed] [Google Scholar]
  8. Harry J. D., Knapp M. F., Linden R. J. The action of ICI-66082 on the heart. Br J Pharmacol. 1973 Jun;48(2):340P–341P. [PMC free article] [PubMed] [Google Scholar]
  9. Harry J. D., Knapp M. F., Linden R. J. The actions of a new beta-adrenoceptor blocking drug, ICI 66082, on the rabbit papillary muscle and on the dog heart. Br J Pharmacol. 1974 Jun;51(2):169–177. doi: 10.1111/j.1476-5381.1974.tb09644.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Malbica J. O., Monson K. R. New and expedient determination of atenolol in biological samples. J Pharm Sci. 1975 Dec;64(12):1992–1994. doi: 10.1002/jps.2600641219. [DOI] [PubMed] [Google Scholar]
  11. Matin S. B., Wan S. H., Karam J. H. Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clin Pharmacol Ther. 1974 Dec;16(6):1052–1058. doi: 10.1002/cpt19741661052. [DOI] [PubMed] [Google Scholar]
  12. McAinsh J. Clinical pharmacokinetics of atenolol. Postgrad Med J. 1977;53 (Suppl 3):74–78. [PubMed] [Google Scholar]
  13. Sassard J., Pozet N., McAinsh J., Legheand J., Zech P. Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol. 1977 Nov 14;12(3):175–180. doi: 10.1007/BF00609856. [DOI] [PubMed] [Google Scholar]
  14. Shanks R. G., Carruthers S. G., Kelly J. G., McDevitt D. G. Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J. 1977;53 (Suppl 3):70–73. [PubMed] [Google Scholar]
  15. Wan S. H., Maronde R. F., Matin S. B. GLC determination of atenolol and beta-blocking agents in biological fluids. J Pharm Sci. 1978 Sep;67(9):1340–1342. doi: 10.1002/jps.2600670947. [DOI] [PubMed] [Google Scholar]
  16. Wan S. H., Matin S. B., Azarnoff D. L. Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. Clin Pharmacol Ther. 1978 May;23(5):585–590. doi: 10.1002/cpt1978235585. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES